购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • BTK
    (1)
  • EGFR
    (1)
  • Isocitrate Dehydrogenase (IDH)
    (1)
  • Mdm2
    (1)
TargetMol | Tags 通过 货期 筛选
  • 现货
    (4)
  • 5日内发货
    (1)
  • 1-2周
    (1)
  • 8-10周
    (1)
抑制剂&激动剂
细分筛选
搜索结果
TargetMol产品目录中 "mutant primary"的结果
筛选
搜索结果
TargetMol产品目录中 "

mutant primary

"的结果
  • 抑制剂&激动剂
    8
    TargetMol | Inhibitors_Agonists
  • 重组蛋白
    2
    TargetMol | Recombinant_Protein
  • Kevetrin hydrochloride
    thioureido butyronitrile hydrochloride, Thioureidobutyronitrile HCl, 4-Isothioureidobutyronitrile hydrochloride
    T318466592-89-0
    Kevetrin hydrochloride (4-Isothioureidobutyronitrile hydrochloride) 是一种小分子,是肿瘤抑制蛋白 p53 的激活剂,具有潜在的抗肿瘤活性。
    • ¥ 179
    In stock
    规格
    数量
  • BI-4020
    T105342664214-60-0In house
    BI-4020 是一种第四代,口服有效,非共价的 EGFR 酪氨酸激酶抑制剂。BI-4020 表现出对三联突变的 EGFR del19 T790M C797S 突变体 ( BaF3 细胞系,IC50=0.2 nM),双重突变的 EGFR del19 T790M 以及单突变的 EGFR del19 (IC50=1 nM)的抑制剂活性。BI-4020 保留了抑制 EGFR wt 的活性 (IC50=190 nM)。BI-4020 具有高激酶组选择性和良好的 DMPK 性质。
    • ¥ 1630
    In stock
    规格
    数量
  • CBR-2092
    TNP2092,CBR2092,TNP-2092,TNP 2092
    T26963922717-97-3
    CBR-2092 is a DNA-directed RNA polymerase and DNA topoisomerase inhibitor. CBR-2092 exhibited rifampin-like potency as an inhibitor of RNA polymerase, was an equipotent (balanced) inhibitor of DNA gyrase and DNA topoisomerase IV, and retained activity against a prevalent quinolone-resistant variant. Studies of mutant strains that exhibited reduced susceptibility to CBR-2092 further substantiated RNA polymerase as the primary cellular target of CBR-2092, with DNA gyrase and DNA topoisomerase IV being secondary and tertiary targets, respectively, in strains exhibiting preexisting rifampin resistance.
    • ¥ 10600
    待询
    规格
    数量
  • FI-700
    T68497866883-79-6
    FI-700 is a novel and potent FLT3 inhibitor with promising antileukemia activity. FI-700 showed a potent IC(50) value against FLT3 kinase at 20 nmol L in an in vitro kinase assay. FI-700 showed selective growth inhibition against mutant FLT3-expressing leukemia cell lines and primary acute myeloid leukemia cells, whereas it did not affect the FLT3 ligand (FL)-driven growth of Wt-FLT3-expressing cells. Oral administration of FI-700 induced the regression of tumors in a s.c. tumor xenograft model and increased the survival of mice in an i.v. transplanted model. Furthermore, FI-700 treatment eradicated FLT3 ITD-expressing leukemia cells, both in the peripheral blood and in the bone marrow. (Source: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4575-82.)
    • ¥ 13900
    8-10周
    规格
    数量
  • AZD3229 Tosylate
    T718942248003-71-4
    AZD3229 Tosylate is a highly potent inhibitor targeting mutant forms of the pan-KIT enzyme, with a primary application in the treatment of gastrointestinal stromal tumors (GISTs).
    • ¥ 5650
    1-2周
    规格
    数量
  • NX-2127
    NX2127, NX 2127
    T734632416131-46-7
    NX-2127 (ETX2514 Triethylamine) 是一种口服有效的 BTK 抑制剂,可诱导细胞中突变的 BTKC481S 降解。NX-2127 具有有效的抗增殖活性,可抑制 BTKC481S 突变体 TMD8 细胞的增殖。NX-2127 有效催化 Ikaros (IKZF1) 和 Aiolos (IKZF3) 降解,作用浓度分别为 25 nM 和 54 nM。NX-2127 与免疫系统有关,刺激 T 细胞活化并增加原代人 T 细胞中 IL-2 的产生。
    • ¥ 987
    In stock
    规格
    数量
  • IHMT-IDH1-053
    T78758
    IHMT-IDH1-053(compound 16)为高选择性不可逆IDH1R132H突变抑制剂,IC50值仅为4.7 nM。对IDH1wt和IDH2wt 突变体活性低。该化合物在IDH1R132H突变293T细胞中显著抑制2-羟基戊二酸(2-HG)生成,IC50为28 nM。IHMT-IDH1-053通过与IDH1R132H蛋白的Cys269残基形成共价键,结合至NADPH结合袋附近的变构袋。此外,它能够抑制携带IDH1R132突变的HT1080细胞系及原代AML细胞增殖。
    • 待询
    规格
    数量
  • UCM-13369
    T875912921944-77-4
    UCM-13369 (Compound 4b) 作为一种NPM1抑制剂,它能特异性地针对 NPM1 C+ 的 C 端 DNA 结合域,并下调其相关信号通路。此外,UCM-13369 还能诱导 AML 细胞系与原代细胞的凋亡,对于AML的研究具有重要用途。
    • 待询
    10-14周
    规格
    数量
没有更多数据了